1.	A Study of Infliximab for Treatment Resistant Major Depression Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care Status: Completed Age: 25 to 60 Sponsor: Other Protocol IDs: IRB00011734, 1R21MH77172-01A2, NCT00463580
2.	Phase III Randomized Study of Docetaxel With or Without Infliximab in Elderly or Poor Performance Status Patients With Wasting, Anorexia, and Asthenia Related to Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: Adult Sponsor: NCI Protocol IDs: NCCTG-N01C9, NCI-P02-0226, N01C9, NCT00040885
3.	Infliximab in Treating Patients With Myelodysplastic Syndrome Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-06023, NCT00074074
4.	A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR004798, NCT00060502
5.	Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer Phase: Phase II Type: Supportive care Status: Completed Age: 45 to 65 Sponsor: NCI, Other Protocol IDs: CDR0000428460, P30CA016042, UCLA-0410033-01, NCT00112749
6.	Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Completed Age: No age specified Sponsor: NCI, Other Protocol IDs: VICC MEL0651, VU-VICC-MEL-0651, VU-VICC-060614, NCT00897312